SlideShare ist ein Scribd-Unternehmen logo
1 von 18
Joint National Committe-7
Recommendations
Noel.M.Isaac
ABSTRACT
In 2003, the Joint National Committee on Prevention,
Detection, Evaluation, and Treatment of High Blood Pressure
(JNC) issued its seventh report, which provided guidelines for
the diagnosis and management of this disease. Included in the
guidelines were: a new classification system for hypertension;
recommendations for lifestyle modifications; and recom-
mendations for pharmacologic therapy.
CHANGES IN BLOOD PRESSURE CLASSIFICATION
In the JNC 7 guidelines, the 7 categories of blood
Pressure(BP)
defined in JNC 6 were simplified and reduced to 4
categories-
• Normal blood pressure: SBP <120 mm Hg and
diastolic blood pressure (DBP) <80 mm Hg
• Prehypertension: These are patients on the cusp of
developing hypertension. It is defined as a SBP of
120-139 mm Hg or a DBP of 80-89 mm Hg
• Stage I hypertension: SBP 140-159 mm Hg or DBP
90-99 mm Hg
• Stage II hypertension: SBP ≥160 mm Hg or DBP
≥ 100 mm Hg
TREATMENT ALGORITHM FOR HYPERTENSION
 In the pre-hypertensive stage:
Lifestyle modifications alone are recommended
 Stage I hypertension:
Lifestyle modifications combined with single-
drug therapy(usually a thiazide-type diuretic) is
recommended.
 Stage II hypertension:
Lifestyle modifications are recommended,
but initial therapy is aggressive, and typically
includes a thiazide type diuretic in combination with
an ACE inhibitor ARB,CCB, or a beta-blocker.
LIFE STYLE MODIFICATION
• Weight Reduction
Maintaining a normal body mass index (18.5-24.9 kg/m2)
helps control blood pressure. In fact, SBP can be reduced between 5-
10 mm Hg for every 10 kg of body weight that is lost.
• Diet
The Dietary Approaches to Stop Hypertension (DASH)diet is a plan that
emphasizes eating fruits, vegetables, and low fat dairy products
while discouraging the consumption of saturated and total fats. It is associate
d with reductions in SBP ranging from 8-14 mm Hg, and can help reduce and
control weight and sodium intake.
LIFE STYLE MODIFICATION
• Dietary Sodium Intake
Current recommendation is to limit the sodium intake to less than 2.4g per
day which helps in the mean BP reduction by 5/2.7mm Hg.
• Regular physical activity
Regular physical activity must be done atleast 30 min/day or atleast 5 days a
week. This will help reduce the systolic blood pressure(SBP) by 9mm Hg
• Moderate alcohol consumption
JNC 7 defines 2 drinks as 24oz of beer, 10 oz of wine, and 3 oz of 80 proof
whisky. Consumption of 1-2 drinks per day decreases the SBP but greater
than 2 drinks may increase the SBP.
Class Drug Usual dose range, mg/day Usual daily frequency*
Diuretics
Loop diuretics Bumetanide
Furosemide
Torsemide
0.5-2
20-80
5-40
2
2
1
Potassium-sparing diuretics Amiloride
Triamterene
5-10
50-100
1-2
1-2
Thiazide and thiazide-like diuretics Chlorthalidone
Hydrochlorothiazide
Indapamide
Metolazone
12.5-25
12.5-50
1.25-2.5
0.5-5
1
1
1
1
ACE Inhibitors Benazepril
Captopril
Enalapril
Fosinopril
Lisinopril
Moexipril
Perindopril
Quinapril
Ramipril
Trandolapril
10-40
25-100
5-40
10-40
10-40
7.5-30
4-8
10-80
2.5-20
1-4
1
2-3
1-2
1
1
1
1
1-2
1
1
ARBs Candesartan
Irbesartan
Losartan
Olmesartan
Telmisartan
Valsartan
8-32
150-300
25-100
20-40
20-80
80-320
1
1
1-2
1
1
1
COMMON ANTIHYPERTENSIVE MEDICATIONS AND RECOMMENDED DOSAGES:
Aldosterone receptor blockers Eplerenone
Spironolactone
50-100
25-50
1
1
Beta-blockers Atenolol
Bisoprolol
Metoprolol
Nadolol
Propranolol
Carvedilol
25-100
2.5-10
50-100
40-120
40-160
12.5-50
1-2
1
1-2
1
2
2
Calcium channel blockers
Dihydropyridine Amlodipine
Felodipine
Isradipine
Nifedipine (sustained released)
2.5-10
2.5-20
2.5-10
30-60
1
1
2
1-2
Nondihydropyridine Diltiazem (extended release)
Verapamil (ER)
180-420
120-360
1
1
Alpha-blockers Doxazosin
Prazosin
Terazosin
1-16
2-20
1-20
1
2-3
1
Direct vasodilators Hydralazine
Minoxidil
25-100
2.5-80
2-3
1-2
COMPELLING INDICATIONS
• Diabetes Mellitus
ACEI/ARBs reduces the risk of progression of DM, and its having reno-
protective activity. ACEI/ARBs can overt diabetic nephropathy and are
therefore considered to be the first line of therapy
Thiazide diuretics, β-blockers or CCBs can be used as an sequential add on
therapy for controlling the blood pressure.
• Chronic Kidney Disease
Initially presents with microalbuminuria-( 30-299mg of albumin in 24hr urine
culture)- which progresses over several years to kidney failure. ACEI/ ARBs
along with diuretics reduces this progression to complete renal failure and
hence used as a first line of therapy.
In case if
 The GFR is <60ml/min,
 Serum creatinine in females is greater than 1.3mg/dl or greater than
1.5mg/dl in men
 Albuminuria-( >300mg/day),
Then typically 3 or more anti hypertensive would be required.
• Acute Coronary Artery Disease
Includes: Unstable angina,
Non-ST segment elevated MI
ST- segment elevated MI
β-blockers decreases the risk of Subsequent MI/ Sudden cardiac
death, therefore considered as first line of therapy.
If there is any presence of AWMI, LVD, or any other condition where BP
lowering is needed then ACEI/ARBs can be given.
• Chronic Coronary Artery Disease
Includes: Post MI
Chronic stable angina
Core regimen= β-blockers + ACEI
ACEI improves cardiac functions and reduces the risk of CV events
• Add on’s:
 Thiazide diuretics, for additional BP reduction
 Dihydropyridine CCBs, for treating ischemic symptoms for those with
chronic stable angina
 Non Dihydopyridine CCBs, for to those whom β-blockers cant be used
• Stroke
ACEI and Thiazide diuretic can reduce the recurrence of stroke in patient
who have had stroke and therefore considered the first line of therapy
• Left Ventricular Dysfunction
ACEI has been found to reduce morbidity and mortality rates in LVD cases
Diuretics is used for the symptomatic treatment of edema
β-blockers has been found to reduce morbidity and mortality rates when
added with ACEI and a Diuretic.
 Standard first line: ACEI + β-blockers + Diuretics.
However only metoprolol, carvedilol and bisoprolol should be used
Add on’s: Aldosterone antagonist.
Compelling
indication
Diuretic Beta-
blockers
ACE
inhibitors
ARBs CCB Aldosterone
blockers
Clinical trial supporting
Heart Failure
• • • • • ACC/AHA Heart Failure
Guidelines, COPERNICUS,
SOLVD,ValHEFT, CHARM,
RALES
Post-MI
• • • • ACC/AHA Post MI Guidelines,
Capricorn, SAVE,VALIANT,
EPHESUS
High Coronary
Risk
• • • • • ALLHAT, HOPE, LIFE, EUROPA,
ONTARGET
Chronic Kidney
Disease
• • • NKF HTN Guidelines, REIN,
ROAD, RENAAL
Stroke
• • • ALLHAT, PROGRESS, MOSES,
LIFE
Diabetes
• • IRMA-2, Micro-HOPE
Elderly
• • SHEP, Sys-EURO
CLINICAL TRIAL AND GUIDELINE BASIS FOR COMPELLING INDICATIONS FOR INDIVIDUAL DRUG
CLASSES
CONCLUSION
Hypertension is among the most commonly encountered
disorders in the ambulatory setting. The guidelines from the
JNC 7 are practical and easily applied to hypertensive patients.
Compliance with the guidelines will result in improved patient
outcomes.
Joint national committe 7

Weitere ähnliche Inhalte

Was ist angesagt?

1.6.2 Pharmacologic Treatment
1.6.2 Pharmacologic Treatment1.6.2 Pharmacologic Treatment
1.6.2 Pharmacologic Treatment
medicinaudm
 
Jnc 7 vs jnc-8
Jnc 7 vs jnc-8Jnc 7 vs jnc-8
Jnc 7 vs jnc-8
Ramachandra Barik
 
hypertension treatment update
hypertension treatment updatehypertension treatment update
hypertension treatment update
Basem Enany
 

Was ist angesagt? (19)

Mellss ho surgery fluid imbalance
Mellss ho surgery fluid imbalanceMellss ho surgery fluid imbalance
Mellss ho surgery fluid imbalance
 
1.6.2 Pharmacologic Treatment
1.6.2 Pharmacologic Treatment1.6.2 Pharmacologic Treatment
1.6.2 Pharmacologic Treatment
 
Jnc 7 vs jnc-8
Jnc 7 vs jnc-8Jnc 7 vs jnc-8
Jnc 7 vs jnc-8
 
Heart Failure- Clinical Therapeutics
Heart Failure- Clinical TherapeuticsHeart Failure- Clinical Therapeutics
Heart Failure- Clinical Therapeutics
 
hypertension treatment update
hypertension treatment updatehypertension treatment update
hypertension treatment update
 
Mellss med hypertension
Mellss med hypertensionMellss med hypertension
Mellss med hypertension
 
Recent advances in treatment of htn
Recent advances in treatment of htnRecent advances in treatment of htn
Recent advances in treatment of htn
 
Drugsused in Cardiovascular System
Drugsused in Cardiovascular SystemDrugsused in Cardiovascular System
Drugsused in Cardiovascular System
 
Anti htn medication.pptx maqsood
Anti htn medication.pptx maqsoodAnti htn medication.pptx maqsood
Anti htn medication.pptx maqsood
 
Diuretic resistance im lecture series 2016
Diuretic resistance  im lecture series 2016Diuretic resistance  im lecture series 2016
Diuretic resistance im lecture series 2016
 
NurseReview.Org - Antihypertensives Updates (pharmacology review notes)
NurseReview.Org - Antihypertensives Updates (pharmacology review notes)NurseReview.Org - Antihypertensives Updates (pharmacology review notes)
NurseReview.Org - Antihypertensives Updates (pharmacology review notes)
 
Lisinopril  - Summary of Product Characteristics
Lisinopril  - Summary of Product CharacteristicsLisinopril  - Summary of Product Characteristics
Lisinopril  - Summary of Product Characteristics
 
Hypertension Guidelines By Rodgers Chibale
Hypertension Guidelines By Rodgers ChibaleHypertension Guidelines By Rodgers Chibale
Hypertension Guidelines By Rodgers Chibale
 
Dyslipidemia Guidlines
Dyslipidemia GuidlinesDyslipidemia Guidlines
Dyslipidemia Guidlines
 
Hypertension conbinsation therapy 2014
Hypertension conbinsation therapy 2014Hypertension conbinsation therapy 2014
Hypertension conbinsation therapy 2014
 
Are all sartans equal
Are all sartans equalAre all sartans equal
Are all sartans equal
 
Management of Hypertension-Guide line
Management of Hypertension-Guide lineManagement of Hypertension-Guide line
Management of Hypertension-Guide line
 
Cardiovascular+pharmacology+drug+therapy+of+hypertension
Cardiovascular+pharmacology+drug+therapy+of+hypertensionCardiovascular+pharmacology+drug+therapy+of+hypertension
Cardiovascular+pharmacology+drug+therapy+of+hypertension
 
Hypertension
HypertensionHypertension
Hypertension
 

Ähnlich wie Joint national committe 7

Hypertension KSU medical college
Hypertension KSU medical collegeHypertension KSU medical college
Hypertension KSU medical college
KhalafAlGhamdi
 

Ähnlich wie Joint national committe 7 (20)

Management and prevention of T2DM and Hypertension
Management and prevention of T2DM and HypertensionManagement and prevention of T2DM and Hypertension
Management and prevention of T2DM and Hypertension
 
Management of Hypertension in Diabetic Patients with Chronic Kidney Disease: ...
Management of Hypertension in Diabetic Patients with Chronic Kidney Disease: ...Management of Hypertension in Diabetic Patients with Chronic Kidney Disease: ...
Management of Hypertension in Diabetic Patients with Chronic Kidney Disease: ...
 
Management of Hypertension in Diabetic Patients with Chronic Kidney Disease: ...
Management of Hypertension in Diabetic Patients with Chronic Kidney Disease: ...Management of Hypertension in Diabetic Patients with Chronic Kidney Disease: ...
Management of Hypertension in Diabetic Patients with Chronic Kidney Disease: ...
 
Blood Pressure Discussion
Blood Pressure DiscussionBlood Pressure Discussion
Blood Pressure Discussion
 
110/04/15-從基層新代科觀點看血壓
110/04/15-從基層新代科觀點看血壓110/04/15-從基層新代科觀點看血壓
110/04/15-從基層新代科觀點看血壓
 
Hypertension Management
Hypertension ManagementHypertension Management
Hypertension Management
 
Drug Prescription in hypertension
Drug Prescription in hypertension Drug Prescription in hypertension
Drug Prescription in hypertension
 
Ckd 2016 100 2
Ckd 2016 100 2Ckd 2016 100 2
Ckd 2016 100 2
 
Hypertension
HypertensionHypertension
Hypertension
 
Hypertension KSU medical college
Hypertension KSU medical collegeHypertension KSU medical college
Hypertension KSU medical college
 
Htn & Diabetes1
Htn & Diabetes1Htn & Diabetes1
Htn & Diabetes1
 
HYPERTENSIVE NEPHROPATHY.pptx
HYPERTENSIVE NEPHROPATHY.pptxHYPERTENSIVE NEPHROPATHY.pptx
HYPERTENSIVE NEPHROPATHY.pptx
 
New Hypertension Guidelines
New Hypertension GuidelinesNew Hypertension Guidelines
New Hypertension Guidelines
 
Combination Therapy In Hypertension - Dr Vivek Baliga Presentation
Combination Therapy In Hypertension - Dr Vivek Baliga PresentationCombination Therapy In Hypertension - Dr Vivek Baliga Presentation
Combination Therapy In Hypertension - Dr Vivek Baliga Presentation
 
Htn1
Htn1Htn1
Htn1
 
combinatintherapyhypertension-baliga.pdf
combinatintherapyhypertension-baliga.pdfcombinatintherapyhypertension-baliga.pdf
combinatintherapyhypertension-baliga.pdf
 
Hypertension guidelines
Hypertension guidelinesHypertension guidelines
Hypertension guidelines
 
Telmisartan combination uses
Telmisartan combination usesTelmisartan combination uses
Telmisartan combination uses
 
Hypertension; Basics- Recommendations - Special Situations
Hypertension; Basics-  Recommendations - Special SituationsHypertension; Basics-  Recommendations - Special Situations
Hypertension; Basics- Recommendations - Special Situations
 
HypertensionCAD Management Cilacar M.pptx
HypertensionCAD Management Cilacar M.pptxHypertensionCAD Management Cilacar M.pptx
HypertensionCAD Management Cilacar M.pptx
 

Kürzlich hochgeladen

Jual Obat Aborsi Hongkong ( Asli No.1 ) 085657271886 Obat Penggugur Kandungan...
Jual Obat Aborsi Hongkong ( Asli No.1 ) 085657271886 Obat Penggugur Kandungan...Jual Obat Aborsi Hongkong ( Asli No.1 ) 085657271886 Obat Penggugur Kandungan...
Jual Obat Aborsi Hongkong ( Asli No.1 ) 085657271886 Obat Penggugur Kandungan...
ZurliaSoop
 

Kürzlich hochgeladen (20)

Towards a code of practice for AI in AT.pptx
Towards a code of practice for AI in AT.pptxTowards a code of practice for AI in AT.pptx
Towards a code of practice for AI in AT.pptx
 
How to setup Pycharm environment for Odoo 17.pptx
How to setup Pycharm environment for Odoo 17.pptxHow to setup Pycharm environment for Odoo 17.pptx
How to setup Pycharm environment for Odoo 17.pptx
 
How to Create and Manage Wizard in Odoo 17
How to Create and Manage Wizard in Odoo 17How to Create and Manage Wizard in Odoo 17
How to Create and Manage Wizard in Odoo 17
 
Kodo Millet PPT made by Ghanshyam bairwa college of Agriculture kumher bhara...
Kodo Millet  PPT made by Ghanshyam bairwa college of Agriculture kumher bhara...Kodo Millet  PPT made by Ghanshyam bairwa college of Agriculture kumher bhara...
Kodo Millet PPT made by Ghanshyam bairwa college of Agriculture kumher bhara...
 
Single or Multiple melodic lines structure
Single or Multiple melodic lines structureSingle or Multiple melodic lines structure
Single or Multiple melodic lines structure
 
Micro-Scholarship, What it is, How can it help me.pdf
Micro-Scholarship, What it is, How can it help me.pdfMicro-Scholarship, What it is, How can it help me.pdf
Micro-Scholarship, What it is, How can it help me.pdf
 
Wellbeing inclusion and digital dystopias.pptx
Wellbeing inclusion and digital dystopias.pptxWellbeing inclusion and digital dystopias.pptx
Wellbeing inclusion and digital dystopias.pptx
 
Mehran University Newsletter Vol-X, Issue-I, 2024
Mehran University Newsletter Vol-X, Issue-I, 2024Mehran University Newsletter Vol-X, Issue-I, 2024
Mehran University Newsletter Vol-X, Issue-I, 2024
 
ICT role in 21st century education and it's challenges.
ICT role in 21st century education and it's challenges.ICT role in 21st century education and it's challenges.
ICT role in 21st century education and it's challenges.
 
TỔNG ÔN TẬP THI VÀO LỚP 10 MÔN TIẾNG ANH NĂM HỌC 2023 - 2024 CÓ ĐÁP ÁN (NGỮ Â...
TỔNG ÔN TẬP THI VÀO LỚP 10 MÔN TIẾNG ANH NĂM HỌC 2023 - 2024 CÓ ĐÁP ÁN (NGỮ Â...TỔNG ÔN TẬP THI VÀO LỚP 10 MÔN TIẾNG ANH NĂM HỌC 2023 - 2024 CÓ ĐÁP ÁN (NGỮ Â...
TỔNG ÔN TẬP THI VÀO LỚP 10 MÔN TIẾNG ANH NĂM HỌC 2023 - 2024 CÓ ĐÁP ÁN (NGỮ Â...
 
REMIFENTANIL: An Ultra short acting opioid.pptx
REMIFENTANIL: An Ultra short acting opioid.pptxREMIFENTANIL: An Ultra short acting opioid.pptx
REMIFENTANIL: An Ultra short acting opioid.pptx
 
Basic Civil Engineering first year Notes- Chapter 4 Building.pptx
Basic Civil Engineering first year Notes- Chapter 4 Building.pptxBasic Civil Engineering first year Notes- Chapter 4 Building.pptx
Basic Civil Engineering first year Notes- Chapter 4 Building.pptx
 
2024-NATIONAL-LEARNING-CAMP-AND-OTHER.pptx
2024-NATIONAL-LEARNING-CAMP-AND-OTHER.pptx2024-NATIONAL-LEARNING-CAMP-AND-OTHER.pptx
2024-NATIONAL-LEARNING-CAMP-AND-OTHER.pptx
 
UGC NET Paper 1 Mathematical Reasoning & Aptitude.pdf
UGC NET Paper 1 Mathematical Reasoning & Aptitude.pdfUGC NET Paper 1 Mathematical Reasoning & Aptitude.pdf
UGC NET Paper 1 Mathematical Reasoning & Aptitude.pdf
 
SOC 101 Demonstration of Learning Presentation
SOC 101 Demonstration of Learning PresentationSOC 101 Demonstration of Learning Presentation
SOC 101 Demonstration of Learning Presentation
 
HMCS Max Bernays Pre-Deployment Brief (May 2024).pptx
HMCS Max Bernays Pre-Deployment Brief (May 2024).pptxHMCS Max Bernays Pre-Deployment Brief (May 2024).pptx
HMCS Max Bernays Pre-Deployment Brief (May 2024).pptx
 
Jual Obat Aborsi Hongkong ( Asli No.1 ) 085657271886 Obat Penggugur Kandungan...
Jual Obat Aborsi Hongkong ( Asli No.1 ) 085657271886 Obat Penggugur Kandungan...Jual Obat Aborsi Hongkong ( Asli No.1 ) 085657271886 Obat Penggugur Kandungan...
Jual Obat Aborsi Hongkong ( Asli No.1 ) 085657271886 Obat Penggugur Kandungan...
 
Sensory_Experience_and_Emotional_Resonance_in_Gabriel_Okaras_The_Piano_and_Th...
Sensory_Experience_and_Emotional_Resonance_in_Gabriel_Okaras_The_Piano_and_Th...Sensory_Experience_and_Emotional_Resonance_in_Gabriel_Okaras_The_Piano_and_Th...
Sensory_Experience_and_Emotional_Resonance_in_Gabriel_Okaras_The_Piano_and_Th...
 
Fostering Friendships - Enhancing Social Bonds in the Classroom
Fostering Friendships - Enhancing Social Bonds  in the ClassroomFostering Friendships - Enhancing Social Bonds  in the Classroom
Fostering Friendships - Enhancing Social Bonds in the Classroom
 
How to Add New Custom Addons Path in Odoo 17
How to Add New Custom Addons Path in Odoo 17How to Add New Custom Addons Path in Odoo 17
How to Add New Custom Addons Path in Odoo 17
 

Joint national committe 7

  • 2. ABSTRACT In 2003, the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC) issued its seventh report, which provided guidelines for the diagnosis and management of this disease. Included in the guidelines were: a new classification system for hypertension; recommendations for lifestyle modifications; and recom- mendations for pharmacologic therapy.
  • 3. CHANGES IN BLOOD PRESSURE CLASSIFICATION In the JNC 7 guidelines, the 7 categories of blood Pressure(BP) defined in JNC 6 were simplified and reduced to 4 categories- • Normal blood pressure: SBP <120 mm Hg and diastolic blood pressure (DBP) <80 mm Hg • Prehypertension: These are patients on the cusp of developing hypertension. It is defined as a SBP of 120-139 mm Hg or a DBP of 80-89 mm Hg • Stage I hypertension: SBP 140-159 mm Hg or DBP 90-99 mm Hg • Stage II hypertension: SBP ≥160 mm Hg or DBP ≥ 100 mm Hg
  • 4. TREATMENT ALGORITHM FOR HYPERTENSION  In the pre-hypertensive stage: Lifestyle modifications alone are recommended  Stage I hypertension: Lifestyle modifications combined with single- drug therapy(usually a thiazide-type diuretic) is recommended.  Stage II hypertension: Lifestyle modifications are recommended, but initial therapy is aggressive, and typically includes a thiazide type diuretic in combination with an ACE inhibitor ARB,CCB, or a beta-blocker.
  • 5. LIFE STYLE MODIFICATION • Weight Reduction Maintaining a normal body mass index (18.5-24.9 kg/m2) helps control blood pressure. In fact, SBP can be reduced between 5- 10 mm Hg for every 10 kg of body weight that is lost. • Diet The Dietary Approaches to Stop Hypertension (DASH)diet is a plan that emphasizes eating fruits, vegetables, and low fat dairy products while discouraging the consumption of saturated and total fats. It is associate d with reductions in SBP ranging from 8-14 mm Hg, and can help reduce and control weight and sodium intake.
  • 6. LIFE STYLE MODIFICATION • Dietary Sodium Intake Current recommendation is to limit the sodium intake to less than 2.4g per day which helps in the mean BP reduction by 5/2.7mm Hg. • Regular physical activity Regular physical activity must be done atleast 30 min/day or atleast 5 days a week. This will help reduce the systolic blood pressure(SBP) by 9mm Hg • Moderate alcohol consumption JNC 7 defines 2 drinks as 24oz of beer, 10 oz of wine, and 3 oz of 80 proof whisky. Consumption of 1-2 drinks per day decreases the SBP but greater than 2 drinks may increase the SBP.
  • 7. Class Drug Usual dose range, mg/day Usual daily frequency* Diuretics Loop diuretics Bumetanide Furosemide Torsemide 0.5-2 20-80 5-40 2 2 1 Potassium-sparing diuretics Amiloride Triamterene 5-10 50-100 1-2 1-2 Thiazide and thiazide-like diuretics Chlorthalidone Hydrochlorothiazide Indapamide Metolazone 12.5-25 12.5-50 1.25-2.5 0.5-5 1 1 1 1 ACE Inhibitors Benazepril Captopril Enalapril Fosinopril Lisinopril Moexipril Perindopril Quinapril Ramipril Trandolapril 10-40 25-100 5-40 10-40 10-40 7.5-30 4-8 10-80 2.5-20 1-4 1 2-3 1-2 1 1 1 1 1-2 1 1 ARBs Candesartan Irbesartan Losartan Olmesartan Telmisartan Valsartan 8-32 150-300 25-100 20-40 20-80 80-320 1 1 1-2 1 1 1 COMMON ANTIHYPERTENSIVE MEDICATIONS AND RECOMMENDED DOSAGES:
  • 8. Aldosterone receptor blockers Eplerenone Spironolactone 50-100 25-50 1 1 Beta-blockers Atenolol Bisoprolol Metoprolol Nadolol Propranolol Carvedilol 25-100 2.5-10 50-100 40-120 40-160 12.5-50 1-2 1 1-2 1 2 2 Calcium channel blockers Dihydropyridine Amlodipine Felodipine Isradipine Nifedipine (sustained released) 2.5-10 2.5-20 2.5-10 30-60 1 1 2 1-2 Nondihydropyridine Diltiazem (extended release) Verapamil (ER) 180-420 120-360 1 1 Alpha-blockers Doxazosin Prazosin Terazosin 1-16 2-20 1-20 1 2-3 1 Direct vasodilators Hydralazine Minoxidil 25-100 2.5-80 2-3 1-2
  • 9. COMPELLING INDICATIONS • Diabetes Mellitus ACEI/ARBs reduces the risk of progression of DM, and its having reno- protective activity. ACEI/ARBs can overt diabetic nephropathy and are therefore considered to be the first line of therapy Thiazide diuretics, β-blockers or CCBs can be used as an sequential add on therapy for controlling the blood pressure.
  • 10. • Chronic Kidney Disease Initially presents with microalbuminuria-( 30-299mg of albumin in 24hr urine culture)- which progresses over several years to kidney failure. ACEI/ ARBs along with diuretics reduces this progression to complete renal failure and hence used as a first line of therapy. In case if  The GFR is <60ml/min,  Serum creatinine in females is greater than 1.3mg/dl or greater than 1.5mg/dl in men  Albuminuria-( >300mg/day), Then typically 3 or more anti hypertensive would be required.
  • 11. • Acute Coronary Artery Disease Includes: Unstable angina, Non-ST segment elevated MI ST- segment elevated MI β-blockers decreases the risk of Subsequent MI/ Sudden cardiac death, therefore considered as first line of therapy. If there is any presence of AWMI, LVD, or any other condition where BP lowering is needed then ACEI/ARBs can be given.
  • 12. • Chronic Coronary Artery Disease Includes: Post MI Chronic stable angina Core regimen= β-blockers + ACEI ACEI improves cardiac functions and reduces the risk of CV events
  • 13. • Add on’s:  Thiazide diuretics, for additional BP reduction  Dihydropyridine CCBs, for treating ischemic symptoms for those with chronic stable angina  Non Dihydopyridine CCBs, for to those whom β-blockers cant be used
  • 14. • Stroke ACEI and Thiazide diuretic can reduce the recurrence of stroke in patient who have had stroke and therefore considered the first line of therapy
  • 15. • Left Ventricular Dysfunction ACEI has been found to reduce morbidity and mortality rates in LVD cases Diuretics is used for the symptomatic treatment of edema β-blockers has been found to reduce morbidity and mortality rates when added with ACEI and a Diuretic.  Standard first line: ACEI + β-blockers + Diuretics. However only metoprolol, carvedilol and bisoprolol should be used Add on’s: Aldosterone antagonist.
  • 16. Compelling indication Diuretic Beta- blockers ACE inhibitors ARBs CCB Aldosterone blockers Clinical trial supporting Heart Failure • • • • • ACC/AHA Heart Failure Guidelines, COPERNICUS, SOLVD,ValHEFT, CHARM, RALES Post-MI • • • • ACC/AHA Post MI Guidelines, Capricorn, SAVE,VALIANT, EPHESUS High Coronary Risk • • • • • ALLHAT, HOPE, LIFE, EUROPA, ONTARGET Chronic Kidney Disease • • • NKF HTN Guidelines, REIN, ROAD, RENAAL Stroke • • • ALLHAT, PROGRESS, MOSES, LIFE Diabetes • • IRMA-2, Micro-HOPE Elderly • • SHEP, Sys-EURO CLINICAL TRIAL AND GUIDELINE BASIS FOR COMPELLING INDICATIONS FOR INDIVIDUAL DRUG CLASSES
  • 17. CONCLUSION Hypertension is among the most commonly encountered disorders in the ambulatory setting. The guidelines from the JNC 7 are practical and easily applied to hypertensive patients. Compliance with the guidelines will result in improved patient outcomes.